SLC5A2 and ventricular fibrillation: In 2022, Tianyou Qin and collaborators have shown that administration of Dapaglifozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, significantly decreased ventricular fibrosis and attenuated NFκB activity while preventing ventricular arrhythmias and VF vulnerability [127] (Table 1).